BRCA2 mutation, a genetic risk factor for breast and ovarian cancer, has been implicated in squamous cell lung cancer among cigarette smokers.
BRCA2
The gene is known to increase risk for breast and ovarian cancers.
Genetic bad actor has been implicated in yet another cancer.
BRCA2
Now, as a new genomic study shows, a rare variant of the gene is associated with increased risk for squamous cell lung cancer, particularly among cigarette smokers.
"This variant confers one the strongest associations found to date for cancer among those identified by genome-wide association studies and identifies a subset of people who are particularly susceptible to harm associated with smoking," said Christopher Amos, PhD, director of the Center for Genomic Medicine at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire.
Nature Genetics.
Dr. Amos is senior author of a meta-analysis combining data from 4 genome-wide association studies (GWAS) involving more than 11,000 people with lung cancer. The results were published online June 1 in
Read the report here: http://bit.ly/1l3vktn
Source: Medscape
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen